Cargando…
Real-World Experience of Pembrolizumab Monotherapy in Patients with Recurrent or Persistent Cervical Cancer: A Korean Multi-Center Retrospective Study (KGOG1041)
SIMPLE SUMMARY: Immune checkpoint inhibitors have received considerable interest because of their ability to generate durable response in many intractable malignant solid tumors. The therapeutic results of immune checkpoint inhibitors in recurrent or advanced uterine cervical cancer, which associate...
Autores principales: | Choi, Min Chul, Kim, Yong-Man, Lee, Jeong-Won, Lee, Yong Jae, Suh, Dong Hoon, Lee, Sung Jong, Lee, Taek Sang, Lee, Maria, Park, Dong Choon, Kim, Min Kyu, Lee, Jong-Min, Shim, Seung-Hyuk, Jeon, Seob, Min, Kyung Jin, Kim, Mi Kyung, Kim, Bo Wook, Park, Jeong Yeol, Kim, Byoung-Gie, Kim, Dae Yeon, Kim, Moon-Hong, Kim, Hyun-Soo, Lee, Jung-Yun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693862/ https://www.ncbi.nlm.nih.gov/pubmed/33138190 http://dx.doi.org/10.3390/cancers12113188 |
Ejemplares similares
-
Discrepancy between Cytology and Histology in Cervical Cancer Screening: a Multicenter Retrospective Study (KGOG 1040)
por: Ouh, Yung-Taek, et al.
Publicado: (2021) -
Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052)
por: Kim, Se Ik, et al.
Publicado: (2021) -
A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial
por: Park, Junsik, et al.
Publicado: (2021) -
Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial
por: Lee, Jung-Yun, et al.
Publicado: (2022) -
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
por: Park, Junsik, et al.
Publicado: (2023)